In individuals with inflammatory bowel disease (IBD), bowel cancer can develop from abnormal cell changes (dysplasia). Regular colonoscopies are recommended to identify these early changes, which can be difficult to detect because they are often small and subtle. Dye-based imaging has been used to improve detection, but it requires additional preparation and time. Texture and Colour Enhancement Imaging (TXI) is a newer method available in clinical practice that adjusts brightness, colour, and texture on high-definition cameras. This study will compare TXI with dye-based imaging to assess which approach detects precancerous changes more effectively in patients with IBD.
Patients >16 with inflammatory bowel disease undergoing surveillance colonoscopy.
Patients with Crohn's (L2/L3 Montreal classification) with >50% colonic involvement
Patients with ulcerative colitis with Extensive or left sided disease (E3 or E2 Montreal classification) for at least 8 years or a diagnosis of Primary sclerosing cholangitis concomitant with IBD.
Disease duration <8 years unless a diagnosis of PSC
Incomplete colonoscopy
BBPS <6 or <2 in any segment
MES ≥2 or any variable of the SES-CD is ≥2 or any stenosis for >10cm segment (above the rectum)
Parallel
TXI
Diagnostic testParticipants allocated to the "TXI" group undergo withdrawal using Texture and Colour Enhancement Imaging, while those in the "Dye" group receive withdrawal with Dye chromoendoscopy. Both procedures follow standardized protocols outlined in the study design.
To compare the proportion of patients with at least 1 dysplastic lesion detected using TXI compared with dye chromoendoscopy
The number of dysplastic areas detected during endoscopy
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
